Enhancement of drug absorption by noncharged detergents through membrane and P-glycoprotein binding

Expert Opinion on Drug Metabolism and Toxicology

Volumn 2, Issue 5, 2006, Pages 733-752

  Seelig, Anna ^a   Gerebtzoff, Grégori ^b  

^a UNIVERSITY OF BASEL   (Switzerland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Active efflux; Detergents; Membrane packing density; Modulators; P glycoprotein; Passive influx; Solubilisers; Substrates

Indexed keywords

DETERGENT; GLYCOPROTEIN P; POLOXAMER;

DRUG ABSORPTION; DRUG SOLUBILITY; DRUG UPTAKE; ENZYME SPECIFICITY; IN VITRO STUDY; IN VIVO STUDY; LIPID MEMBRANE; MEMBRANE BINDING; PROTEIN BINDING; REVIEW;

ABSORPTION; ANIMALS; CELL MEMBRANE; DETERGENTS; EXCIPIENTS; HUMANS; P-GLYCOPROTEIN; PHARMACEUTICAL PREPARATIONS; POLOXAMER;

EID: 33845731767     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2.5.733     Document Type: Review

References (103)

1. RIEHM H, BIEDLER JL: Potentiation of drug effect by Tween 80 in Chinese hamster cells resistant to actinomycin D and daunomycin. Cancer Res. (1972) 32(6):1195-1200.
2. FRICHE E, JENSEN PB, SEHESTED M, DEMANT EJ, NISSEN NN: The solvents Cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor. Cancer Commun. (1990) 2(9):297-303.
3. COON JS, KNUDSON W, CLODFELTER K, LU B, WEINSTEIN RS: Solutol HS 15, nontoxic polyoxyethylene esters of 12-hydroxystearic acid, reverses multidrug resistance. Cancer Res. (1991) 51(3):897-902.
4. SPOELSTRA EC, DEKKER H, SCHUURHUIS GJ, BROXTERMAN HJ, LANKELMA J: P-glycoprotein drug efflux pump involved in the mechanisms of intrinsic drug resistance in various colon cancer cell lines. Evidence for a saturation of active daunorubicin transport. Biochem. Pharmacol. (1991) 41(3):349-359.
5. WOODCOCK DM, LINSENMEYER ME, CHOJNOWSKI G et al.: Reversal of multidrug resistance by surfactants. Br. J. Cancer (1992) 66(1):62-68.
6. LOE DW, SHAROM FJ: Interaction of multidrug-resistant Chinese hamster ovary cells with amphiphiles. Br. J. Cancer (1993) 68(2):342-351.
7. ZORDAN-NUDO T, LING V, LIU Z, GEORGES E: Effects of nonionic detergents on P-glycoprotein drug binding and reversal of multidrug resistance. Cancer Res. (1993) 53(24):5994-6000.
8. DRORIS, EYTAN GD, ASSARAF YG: Potentiation of anticancer-drug cytotoxicity by multidrug-resistance chemosensitizers involves alterations in membrane fluidity leading to increased membrane permeability. Eur. J. Biochem. (1995) 228(3):1020-1029.
9. BORREL MN, FIALLO M, VERESS I, GARNIER-SUILLERO T A: The effect of crown ethers, tetraalkylammonium salts, and polyoxyethylene amphiphiles on pirarubicin incorporation in K562 resistant cells. Biochem. Pharmacol. (1995) 50(12):2069-2076.
10. LITMAN T, DRULEY TE, STEIN WD, BATES SE: From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol. Life Sci. (2001) 58(7):931-959.
11. STOUCH TR, GUDMUNDSSON O: Progress in understanding the structure-activity relationships of P-glycoprotein. Adv. Drug Deliv. Rev. (2002) 54(3):315-328.
12. CORDON-CARDOC, O'BRIEN JP, CASALS D et al.: Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. USA (1989) 86(2):695-698.
13. THIEBAUT F, TSURUO T, HAMADA H, GOTTESMAN MM, PASTAN I, WILLINGHAM MC: Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA (1987) 84(21):7735-7738.
14. TANIGAWARA Y: Role of P-glycoprotein in drug disposition. Ther. Drug Monit. (2000) 22(1):137-140.
15. SEELIG A, GATLIK-LANDWOJTOWICZ E: Inhibitors of multidrug efflux transporters: their membrane and protein interactions. Mini Rev. Med. Chem. (2005) 5(2):135-151.
16. DEAN M, HAMON Y, CHIMINI G: The human ATP-binding cassette (ABC) transporter superfamily. J. Lipid Res. (2001) 42(7):1007-1017.
17. ZAMEK-GLISZCZYNSKIMJ, HOFFMASTER KA, NEZASA K, TALLMAN MN, BROUWER KL: Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. Eur. J. Pharm. Sci. (2006) 27(5):447-486.
18. SEELIG A, BLATTER XL, WOHNSLAND F: Substrate recognition by P-glycoprotein and the multidrug resistance-associated protein MRP1: a comparison. Int. J. Clin. Pharmacol. Ther. (2000)38(3):111-121.
19. ZHANG Y, BENET LZ: The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin. Pharmacokinet. (2001) 40(3):159-168.
20. HIGGINS CF, GOTTESMAN MM: Is the multidrug transporter a flippase? Trends Biochcm. Sci. (1992) 17(1):18-21.
21. GATLIK-LANDWOJTOWICZ E, AANISMAA P, SEELIG A: Quantification and characterization of P-glycoprotein-substrate interactions. Biochemistry (2006) 45(9):3020-3032.
22. ORLOWSKI S, SELOSSE MA, BOUDON C et al.: Effects of detergents on P-glycoprotein atpase activity: differences in perturbations of basal and verapamil-dependent activities. Cancer Biochem. Biophys. (1998) 16(1-2):85-110.
23. REGEV R, ASSARAF YG, EYTAN GD: Membrane fluidization by ether, other anesthetics, and certain agents abolishes P-glycoprotein ATPase activity and modulates efflux from multidrug-resistant cells. Eur. J. Biochem. (1999) 259(1-2): 18-24.
24. MEIER M, LI-BLATTER X, SEELIG A, SEELIG J: Interaction of verapamil with lipid membranes and P-glycoprotein. Connecting thermodynamics and membrane structure with functional activity. Biophysical J. (In Press).
25. WAKITA M, KURODA Y, NAKAGAWA T: Interactions between local anesthetic dibucaine and pig erythrocyte membranes as studied by proton and phosphorus-31 nuclear magnetic resonance spectroscopy. Chem. Pharm. Bull. (Tokyo) (1992) 40(6):1361-1365.
26. REGE BD, KAO JP, POLLI JE: Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur. J. Pharm. Sci. (2002) 16(4-5):237-246.
27. NERVI P: Peptide and drug interactions in murine models in vitro and in vivo studies with microphysiometry, confocal microscopy and functional magnetic resonance imaging. PhD Thesis, University of Basel, Switzerland (2004).
28. KABANOV AV, BATRAKOVA EV, MILLER DW: Pluronic block copolymers as modulators of drug efflux transporter activity in the blood-brain barrier. Adv. Drug Deliv. Rev. (2003) 55(1):151-164.
29. SEELIG J, SEELIG A: Lipid conformation in model membranes and biological membranes. Q. Rev. Biophys. (1980) 13(1):19-61.
30. SEELIG A, SEELIG J: Membrane Structure. In: Encyclopedia of Physical Science and Technology, 3rd edn. Academic Press, NY, USA (2002):355-367.
31. LITMAN T, NIELSEN D, SKOVSGAARD T, BUKHAVE K: Lipid composition of sensitive and multidrug resistant Ehrlich ascites tumour cells. Cell. Pharmacol. (1995) 2:9-14.
32. FISCHER H, GOTTSCHLICH R, SEELIG A: Blood-brain barrier permeation: molecular parameters governing passive diffusion. J. Membr. Biol. (1998) 165(3):201-211.
33. FISCHER H, SEELIG A, CHOU RC, VAN DE WATERBEEMD J: The difference between the diffusion through the blood-brain barrier and the gastro-intestinal membrane. 4th International Conference on Drug Absorption. Edinburgh, UK (1997).
34. SEELIG A: Local anesthetics and pressure: a comparison of dibucaine binding to lipid monolayers and bilayers. Biochim. Biophys. Acta (1987) 899(2): 196-204.
35. BOGUSLAVSKY V, REBECCHI M, MORRIS AJ, JHON DY, RHEE SG, MCLAUGHLIN S: Effect of monolayer surface pressure on the activities of phosphoinositide- specific phospholipase C-β1, -γ1, and -δ1. Biochemistry (1994) 33(10):3032-3037.
36. GEREBTZOFF G, LI-BLATTER X, FISCHER H, FRENTZEL A, SEELIG A: Halogenation of drugs enhances membrane binding and permeation. Chembiochem (2004) 5(5):676-684.
37. GOBAS FA, LAHITTETE JM, GAROFALO G, SHIU WY, MACKAY D: A novel method for measuring membrane-water partition coefficients of hydrophobic organic chemicals: comparison with 1-octanol-water partitioning. J. Pharm. Sci. (1988) 77(3):265-272.
38. HEERKLOTZ H, SEELIG J: Correlation of membrane/water partition coefficients of detergents with the critical micelle concentration. Biophys. J. (2000) 78(5):2435-2440.
39. WU G, MAJEWSKI J, EGE C, KJAER K, WEYGAND MJ, LEE KY: Lipid corralling and poloxamer squeeze-out in membranes. Phys. Rev. Lett. (2004) 93(2):028101.
40. MASKARINEC SA, HANNIG J, LEE RC, LEE KY: Direct observation of poloxamer 188 insertion into lipid monolayers. Biophys. J. (2002) 82(3):1453-1459.
41. WU G, MAJEWSKI J, EGE C, KJAER K, WEYGAND MJ, LEE KY: Interaction between lipid monolayers and poloxamer 188: an X-ray reflectivity and diffraction study. Biophys. J. (2005) 89(5):3159-3173.
42. CHANG LC, LIN CY, KUO MW, GAU CS: Interactions of Pluronics with phospholipid monolayers at the air-water interface. J. Colloid Interface Sci. (2005) 285(2):640-652.
43. KRYLOVA OO, POHL P: Ionophoric activity of pluronic block copolymers. Biochemistry (2004) 43(12):3696-3703.
44. DEMINA T, GROZDOVA I, KRYLOVA O et al.: Relationship between the structure of amphiphilic copolymers and their ability to disturb lipid bilayers. Biochemistry (2005) 44(10):4042-4054.
45. BATRAKOVA EV, MILLER DW, LI S, ALAKHOV VY, KABANOV AV, ELMQUIST WF: Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies. J. Pharmacol. Exp. Ther. (2001) 296(2):551-557.
46. OTTEN D, BROWN MF, BEYER K: Softening of membrane bilayers by detergents elucidated by deuterium NMR spectroscopy. J. Phys. Chem. B (2000) 104:12119-12129.
47. THEWALT JL, TULLOCH AP, CUSHLEY RJ: A deuterium NMR study of labelled n-alkanol anesthetics in a model membrane. Chem. Phys. Lipids (1986) 39(1-2):93-107.
48. WENK MR, ALT T, SEELIG A, SEELIG J: Octyl-β-D-glucopyranoside partitioning into lipid bilayers: thermodynamics of binding and structural changes of the bilayer. Biophys. J. (1997) 72(4):1719-1731.
49. HEERKLOTZ H: Triton promotes domain formation in lipid raft mixtures. Biophys. J. (2002) 83(5):2693-2701.
50. WASSALL SR, THEWALT JL, WONG L, GORRISSEN H, CUSHLEY RJ: Deuterium NMR study of the interaction of α-tocopherol with a phospholipid model membrane. Biochemistry (1986) 25(2):319-326.
51. HUGGER ED, NOVAK BL, BURTON PS, AUDUS KL, BORCHARDT RT: A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro. J. Pharm. Sci. (2002) 91(9):1991-2002.
52. LIANG X, MAO G, NG KY: Effect of chain lengths of PEO-PPO-PEO on small unilamellar liposome morphology and stability: an AFM investigation. J. Colloid Interface Sci. (2005) 285(1):360-372.
53. OMOTE H, AL-SHAWI MK: Interaction of transported drugs with the lipid bilayer and P-glycoprotein through a solvation exchange mechanism. Biophys. J. (2006) 90(11):4046-4059.
54. SEELIG A, LANDWOJTOWICZ E, FISCHER H, BLATTER XL: Towards P-glycoprotein structure-activity relationships. In: Drug bioavailability/Estimation of solubility, permeability, absorption and bioavailability. Van der Waterbeemd H, Lennernas H, Arthurson P (Eds), Wiley-VCH Verlag GmbH, Weinheim, Germany (2003).
55. SEELIG A: A general pattern for substrate recognition by P-glycoprotein. Eur. J. Biochem. (1998) 251(1-2):252-261.
56. ECKER G, HUBER M, SCHMID D, CHIBA P: The importance of a nitrogen atom in modulators of multidrug resistance. Mol. Pharmacol. (1999) 56(4):791-796.
57. SEELIG A, LANDWOJTOWICZ E: Structure-activity relationship of P-glycoprotein substrates and modifiers. Eur. J. Pharm. Sci. (2000) 12(1):31-40.
58. CHIBA P, ERKER T, GALANSKI M, HITZLER M, ECKER GF: Synthesis and multidrug-resistancc modulating activity of a series of thienothiazines. Arch. Pharm. (Weinheim) (2002) 335(5):223-228.
59. SEELIG A: Unraveling membrane-mediated substrate-transporter interactions. Biophys. J. (2006) 90(11):3825-3826.
60. LANDWOJTOWICZ E, NERVI P, SEELIG A: Real-time monitoring of P-glycoprotein activation in living cells. Biochemistry (2002) 41(25):8050-8057.
61. AL-SHAWI MK, POLAR MK, OMOTE H, FIGLER RA: Transition state analysis of the coupling of drug transport to ATP hydrolysis by P-glycoprotein. J. Biol. Chem. (2003) 278(52):52629-52640.
62. RAGGERS RJ, POMORSKI T, HOLTHUIS JC, KALIN N, VAN MEER G: Lipid traffic: the ABC of transbilayer movement. Traffic (2000) 1(3):226-234.
63. ROMSICKI Y, SHAROM FJ: Phospholipid flippase activity of the reconstituted P-glycoprotein multidrug transporter. Biochemistry (2001) 40(23):6937-6947.
64. LITMAN T, ZEUTHEN T, SKOVSGAARD T, STEIN WD: Structure-activity relationships of P-glycoprotein interacting drugs: kinetic characterization of their effects on ATPase activity.Biochim. Biophys. Acta (1997)1361(2):159-168.
65. GATLIK-LANDWOJTOWICZ E, AANISMAA P, SEELIG A: The rate of P-glycoprotein activation depends on the metabolic state of the cell. Biochemistry (2004) 43(46):14840-14851.
66. URBATSCH IL, AL-SHAWI MK, SENIOR AE: Characterization of the ATPase activity of purified Chinese hamster P-glycoprotein. Biochemistry (1994)33(23):7069-7076.
67. SHAPIRO AB, LING V: Stoichiometry of coupling of rhodamine 123 transport to ATP hydrolysis by P-glycoprorein. Eur. J. Biochem. (1998) 254(1):189-193.
68. SAUNA ZE, AMBUDKAR SV: Characterization of the catalytic cycle of ATP hydrolysis by human P-glycoprotein. The two ATP hydrolysis events in a single catalytic cycle are kinetically similar but affect different functional outcomes. J. Biol. Chem. (2001) 276(15):11653-11661.
69. NERURKAR MM, HO NF, BURTON PS, VIDMAR TJ, BORCHARDT RT: Mechanistic roles of neutral surfactants on concurrent polarized and passive membrane transport of a model peptide in Caco-2 cells. J. Pharm. Sci. (1997) 86(7):813-821.
70. BRAVO GONZALEZ RC, HUWYLER J, BOESS F, WALTER I, BITTNER B: In vitro investigation on the impact of the surface-active excipients Cremophor EL, Tween 80 and Solutol HS-15 on the metabolism of midazolam. Biopharm. Drug Dispos. (2004) 25(1):37-49.
71. BITTNER B, GONZALEZ RC, WALTER I, KAPPS M, HUWYLER J: Impact of Solutol HS 15 on the pharmacokinetic behaviour of colchicine upon intravenous administration to male Wistar rats. Biopharm. Drug Dispos. (2003) 24(4):173-181.
72. BRAVO GONZALEZ RC, HUWYLER J, WALTER I, MOUNTFIELD R, BITTNER B: Improved oral bioavailability of cyclosporin A in male Wistar rats. Comparison of a Solutol HS 15 containing self-dispersing formulation and a microsuspension. Int. J. Pharm. (2002) 245(1-2):143-151.
73. BITTNER B, GONZALEZ RCB, WALTER I, HUWYLER J: Impact of oral administration of the surface-active excipient solutol HS-15 on the pharmacokinetics of intravenously administered colchicine. Lett. Drug Des. Disc. (2005) 2(3):193-195.
74. WANG SW, MONAGLE J, MCNULTY C, PUTNAM D, CHEN H: Determination of P-glycoprotein inhibition by excipients and their combinations using an integrated high-throughput process. J. Pharm. Sci. (2004) 93(11):2755-2767.
75. DUDEJA PK, ANDERSON KM, HARRIS JS, BUCKINGHAM L, COON JS: Reversal of multidrug resistance phenotype by surfactants: relationship to membrane lipid fluidity. Arch. Biochem. Biophys. (1995) 319(1):309-315.
76. LITMAN T, SKOVSGAARD T, STEIN WD: Pumping of drugs by P-glycoprotein: a two-step process? J. Pharmacol. Exp. Ther. (2003) 307(3):846-853.
77. ATTWOOD D, FLORENCE AT: Surfactant systems: their chemistry, pharmacy and biology. Chapman and Hall, London (UK) and New York (USA) (1983).
78. BOGMAN K, ZYSSET Y, DEGEN L et al.: P-glycoprotein and surfactants: effect on intestinal talinolol absorption. Clin. Pharmacol. Ther. (2005) 77(1):24-32.
79. JAGANNATH C, WELLS A, MSHVILDADZE M et al.: Significantly improved oral uptake of amikacin in FVB mice in the presence of CRL-1605 copolymer. Life Sci. (1999) 64(19):1733-1738.
80. BANERJEE SK, JAGANNATH C, HUNTER RL, DASGUPTA A: Bioavailability of tobramycin after oral delivery in FVB mice using CRL-1605 copolymer, an inhibitor of P-glycoprotein. Life Sci. (2000) 67(16):2011-2016.
81. GAUCHER G, DUFRESNE MH, SANT VP, KANG N, MAYSINGER D, LEROUX JC: Block copolymer micelles: preparation, characterization and application in drug delivery. J. Control. Release (2005) 109(1-3):169-188.
82. GELDERBLOM H, VERWEIJ J, NOOTER K, SPARREBOOM A: Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer (2001) 37(13):1590-1598.
83. COORS EA, SEYBOLD H, MERK HF, MAHLER V: Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions. Ann. Allergy Asthma Immunol. (2005) 95(6):593-599.
84. HAVEL M, MULLER M, GRANINGER W, KURZ R, LINDEMAYR H: Tolerability of a new vitamin K1 preparation for parenteral administration to adults: one case of anaphylactoid reaction. Clin. Ther. (1987) 9(4):373-379.
85. THEIS JG, LIAU-CHU M. CHAN HS, DOYLE J, GREENBERG ML, KOREN G: Anaphylactoid reactions in children receiving high-dose intravenous cyclosporine for reversal of tumor resistance: the causative role of improper dissolution of Cremophor EL. J. Clin. Oncol. (1995) 13(10):2508-2516.
86. PENDSE S, SAYEGH MH, FRANK MH: P-glycoprotein-a novel therapeutic target for immunomodulation in clinical transplantation and autoimmunity? Curr. Drug Targets (2003) 4(6):469-476.
87. BEGLEY GS, HORVATH AR, TAYLOR JC, HIGGINS CF: Cytoplasmic domains of the transporter associated with antigen processing and P-glycoprotein interact with subunits of the proteasome. Mol. Immunol. (2005) 42(1):137-141.
88. COGGER VC, HILMER SN, SULLIVAN D, MULLER M, FRASER R, LE GOUTEUR DG: Hyperlipidemia and surfactants: the liver sieve is a link. Atherosclerosis (2006) (In Press).
89. SEEBALLUCK F, ASHFORD MB, O'DRISCOLL CM: The effects of pluronics block copolymers and Cremophor EL on intestinal lipoprotein processing and the potential link with P-glycoprotein in Caco-2 cells. Pharm. Res. (2003) 20(7):1085-1092.
90. JOHNSON BM, CHARMAN WN, PORTER CJ: An in vitro examination of the impact of polyethylene glycol 400, Pluronic P85, and vitamin E D-α-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine. AAPS PharmSci (2002) 4(4):40.
91. BATRAKOVA EV, LI S, MILLER DW, KABANOV AV: Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers. Pharm. Res. (1999) 16(9):1366-1372.
92. MILLER DW, BATRAKOVA EV, KABANOV AV: Inhibition of multidrug resistance-associated protein (MRP) functional activity with pluronic block copolymers. Pharm. Res. (1999) 16(3):396-401.
93. BOGMAN K, ERNE-BRAND F, ALSENZ J, DREWE J: The role of surfactants in the reversal of active transport mediated by multidrug resistance proteins. J. Pharm. Sci. (2003) 92(6):1250-1261.
94. DEMEL RA, GEURTS VAN KESSEL WS, ZWAAL RF, ROELOFSEN B, VAN DEENEN LL: Relation between various phospholipase actions on human red cell membranes and the interfacial phospholipid pressure in monolayers. Biochim. Biophys. Acta (1975) 406(1):97-107.
95. BLUME A: A comparative study of the phase transitions of phospholipid bilayers and monolayers. Biochim. Biophys. Acta (1979) 557(1):32-44.
96. NERVI P, LI BLATTER X, SEELIG A: Surfactants as P-glycoprotein substrates and inhibitors. (In preparation).
97. BRAVO GONZALEZ RC, BOESS F, DURR E, SCHAUB N, BITTNER B: In vitro investigation on the impact of Solutol HS 15 on the uptake of colchicine into rat hepatocytes. Int. J. Pharm. (2004) 279(1-2):27-31.
98. BITTNER B, GUENZI A, FULLHARDT P, ZUERCHER G, GONZALEZ RC, MOUNTFIELD RJ: Improvement of the bioavailability of colchicine in rats by co-administration of D-α-tocopherol polyethylene glycol 1000 succinate and a polyethoxylated derivative of 12-hydroxy-stearic acid. Arzneimittelfonchung (2002) 52(9):684-688.
99. DINTAMAN JM, SILVERMAN JA: Inhibition of P-glycoprotein by D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm. Res. (1999) 16(10):1550-1556.
100. REBBEOR JF, SENIOR AE: Effects of cardiovascular drugs on ATPase activity of P-glycoprotein in plasma membranes and in purified reconstituted form. Biochim. Biophys. Acta (1998) 1369(1):85-93.
101. LO YL: Relationships between the hydrophilic-lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines. J. Control Release (2003) 90(1):37-48.
102. HIRSCH-ERNST KI, ZIEMANN C, RUSTENBECK I, KAHL GF: Inhibitors of mdr1-dependent transport activity delay accumulation of the mdr1 substrate rhodamine 123 in primary rat hepatocyte cultures. Toxicology (2001) 167(1):47-57.
103. http://www.drugs.com/cons/Poloxamer_188. html Poloxamer 188 Drug Information. Drugsite Trust, NZ (2006).